Skip to main content
Premium Trial:

Request an Annual Quote

Richard DiMarchi, Thomas Daniel, Camron Nezhat

Premium

Richard DiMarchi has been appointed CEO and Thomas Daniel has become chief scientific officer of San Diego-based Ambrx. DiMarchi, one of the founders of Ambrx, was previously group vice president for biotechnology and product development at Lilly Research Laboratories, where he co-invented Humalog, the first biosynthetic protein approved for human use. He is a professor of chemistry at Indiana University and a member of Inproteo.

Daniel was previously vice president of research at Amgen, and was senior vice president of dis-covery research at Immunex before Amgen acquired it. He was also previously a professor of medicine and cell biology at Vanderbilt University and director of the Vanderbilt Center for Vascular Biology.


Camron Nezhat has been appointed to the scientific advisory board of CombiMatrix. Nezhat is a surgeon at Stanford University. He was the inventor of video laparoscopy, a now popular minimally invasive surgical technique for abdominal and pelvic surgery.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.